EP
NBIX icon

Essential Partners’s Neurocrine Biosciences NBIX Stock Holding History

Essential Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Sell
2,060
-3,409
-62% -$506K 0.16% 130
2026
Q1 		$720K Sell
5,469
-636
-10% -$84.4K 0.24% 106
2025
Q4 		$866K Buy
6,105
+588
+11% +$85.2K 0.27% 101
2025
Q3 		$774K Buy
5,517
+2,937
+114% +$398K 0.26% 106
2025
Q2 		$324K Buy
+2,580
New +$296K 0.13% 220

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's NBIX Position: Q2 2026 in Review

Essential Partners reduced its Neurocrine Biosciences (NBIX) stake by 62% in Q2 2026, selling an estimated $506K and leaving 2,060 shares worth $347K. The position accounts for 0.16% of the portfolio, ranked #130.

Essential Partners first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $866K in Q4 2025. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Essential Partners held 2,060 shares of Neurocrine Biosciences worth $347K as of Q2 2026.
  • Essential Partners sold 3,409 Neurocrine Biosciences shares in Q2 2026, an estimated $506K.
  • Neurocrine Biosciences made up 0.16% of Essential Partners's portfolio in Q2 2026, its #130 holding.
  • Essential Partners first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Neurocrine Biosciences position peaked at $866K in Q4 2025.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.